BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25882519)

  • 1. The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents.
    Zhang X; Raghavan S; Ihnat M; Hamel E; Zammiello C; Bastian A; Mooberry SL; Gangjee A
    Bioorg Med Chem; 2015 May; 23(10):2408-23. PubMed ID: 25882519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.
    Gangjee A; Namjoshi OA; Yu J; Ihnat MA; Thorpe JE; Warnke LA
    Bioorg Med Chem; 2008 May; 16(10):5514-28. PubMed ID: 18467105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
    Pavana RK; Choudhary S; Bastian A; Ihnat MA; Bai R; Hamel E; Gangjee A
    Bioorg Med Chem; 2017 Jan; 25(2):545-556. PubMed ID: 27894589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and preclinical evaluation of 5-methyl-N
    Devambatla RKV; Choudhary S; Ihnat M; Hamel E; Mooberry SL; Gangjee A
    Bioorg Med Chem Lett; 2018 Oct; 28(18):3085-3093. PubMed ID: 30098869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents.
    Zhang X; Raghavan S; Ihnat M; Thorpe JE; Disch BC; Bastian A; Bailey-Downs LC; Dybdal-Hargreaves NF; Rohena CC; Hamel E; Mooberry SL; Gangjee A
    Bioorg Med Chem; 2014 Jul; 22(14):3753-72. PubMed ID: 24890652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents.
    Gangjee A; Zhao Y; Raghavan S; Ihnat MA; Disch BC
    Bioorg Med Chem; 2010 Jul; 18(14):5261-73. PubMed ID: 20558072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
    Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
    Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic and antitumor agents. Design, synthesis, and evaluation of novel 2-amino-4-(3-bromoanilino)-6-benzylsubstituted pyrrolo[2,3-d]pyrimidines as inhibitors of receptor tyrosine kinases.
    Gangjee A; Yang J; Ihnat MA; Kamat S
    Bioorg Med Chem; 2003 Nov; 11(23):5155-70. PubMed ID: 14604679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.
    Zhang J; Zhou J; Ren X; Diao Y; Li H; Jiang H; Ding K; Pei D
    Invest New Drugs; 2012 Apr; 30(2):490-507. PubMed ID: 21080210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors.
    Fischer T; Krüger T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2708-2712. PubMed ID: 28478927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological activity of N
    Kurup S; McAllister B; Liskova P; Mistry T; Fanizza A; Stanford D; Slawska J; Keller U; Hoellein A
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):74-84. PubMed ID: 29115879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding the structural diversity of diarylureas as multi-target tyrosine kinase inhibitors.
    Shan Y; Wang C; Zhang L; Wang J; Wang M; Dong Y
    Bioorg Med Chem; 2016 Feb; 24(4):750-8. PubMed ID: 26753815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyrido[2,3-d]pyrimidine scaffold.
    Elzahabi HSA; Nossier ES; Khalifa NM; Alasfoury RA; El-Manawaty MA
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):546-557. PubMed ID: 29482389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
    Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.
    Gangjee A; Zaware N; Raghavan S; Yang J; Thorpe JE; Ihnat MA
    Bioorg Med Chem; 2012 Apr; 20(7):2444-54. PubMed ID: 22370340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.
    Zaware N; Kisliuk R; Bastian A; Ihnat MA; Gangjee A
    Bioorg Med Chem Lett; 2017 Apr; 27(7):1602-1607. PubMed ID: 28258797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase.
    Shi ZH; Liu FT; Tian HZ; Zhang YM; Li NG; Lu T
    Bioorg Med Chem; 2018 Sep; 26(16):4735-4744. PubMed ID: 30121211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluation of novel 3-pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives as potent receptor tyrosine kinase inhibitors.
    Ding L; Tang F; Huang W; Jin Q; Shen H; Wei P
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5630-3. PubMed ID: 23999040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2- d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors.
    Romagnoli R; Prencipe F; Oliva P; Baraldi S; Baraldi PG; Schiaffino Ortega S; Chayah M; Kimatrai Salvador M; Lopez-Cara LC; Brancale A; Ferla S; Hamel E; Ronca R; Bortolozzi R; Mariotto E; Mattiuzzo E; Viola G
    J Med Chem; 2019 Feb; 62(3):1274-1290. PubMed ID: 30633509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of novel oxazolo[5,4-d]pyrimidines as potent VEGFR-2 inhibitors.
    Deng YH; Xu D; Su YX; Cheng YJ; Yang YL; Wang XY; Zhang J; You QD; Sun LP
    Chem Biodivers; 2015 Apr; 12(4):528-37. PubMed ID: 25879498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.